Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

NDAQ:MNMD - Post Discussion

Mind Medicine (MindMed) Inc > Ladies time to change your panties.
View:
Post by elgin1 on Dec 29, 2020 11:32am

Ladies time to change your panties.

Update from newsletter writer . MMED CEO is from Uber ???? Six months ago, MindMed (MMEDF)'s market cap was US$65.13 million. Today, MMEDF's market cap is US$1.06 billion. MMEDF may be applying for patents but BETRF has already been awarded patents protecting its process that allows for cost-effective manufacturing of BOL-148 without the need to make LSD, making BETRF the only entity with the ability to synthesize the drug without the regulatory hurdles of handling a Schedule 1 controlled substance. MMEDF has an inexperienced management team (its CEO previously held a low level job at Uber). BETRF has a highly experienced and successful management team of industry experts.BETRF's CEO Dr. Ahmad Doroudian took the last company he founded Merus Labs to the NASDAQ where it was acquired in 2017 at a 65% premium that valued it at US$270 million.
Comment by GREENBOY on Dec 29, 2020 12:08pm
This post has been removed in accordance with Community Policy
Comment by goldmike on Dec 30, 2020 11:37am
BetterLife Pharma (CSE: BETR). BETR is NIA's #1 overall pick for 2021. Yesterday, BETR began to breakout big and gained by $0.36 or 21.95% to close at $2 per share, its highestclosing price since becoming a psychedelic company! BETR will quickly be launching their IIS in 1Q 2021 ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities